TEC-001 + Opdivo
Liver Cancer (Advanced stage)
About Teclison
Teclison is a private, pre-revenue biotech founded in 2015 and based in San Diego, CA. The company is advancing a novel therapeutic platform that combines tumor-hypoxia-inducing procedures with immune system activation to treat solid tumors, with a lead program (TEC-001) in Phase 2 trials for various cancers including hepatocellular carcinoma (HCC). Teclison has a strategic collaboration with Merck and is targeting a significant unmet need in patients who respond poorly to current immunotherapies.
View full company profileAbout Teclison
Teclison is a private, pre-revenue biotech founded in 2015 and based in San Diego, CA. The company is advancing a novel therapeutic platform that combines tumor-hypoxia-inducing procedures with immune system activation to treat solid tumors, with a lead program (TEC-001) in Phase 2 trials for various cancers including hepatocellular carcinoma (HCC). Teclison has a strategic collaboration with Merck and is targeting a significant unmet need in patients who respond poorly to current immunotherapies.
View full company profile